University of California, San Francisco: Leukemia trials
The registry lists 18 Leukemia studies with University of California, San Francisco as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 6Phase 2 6No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell TransplantationCompletedNCT02458235Phase 2Results posted
- A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic MalignanciesCompletedNCT01036009Phase 2Results posted
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 2Results posted
- A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase InhibitorsCompletedNCT04605211Not applicable
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep RegimenCompletedNCT01048827Phase 1
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesTerminatedNCT00514722Not applicable
- Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic MalignanciesTerminatedNCT00513318
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic CancerTerminatedNCT00301860Not applicable
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaStatus unknownNCT00295997Not applicable
- Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseCompletedNCT00295971Phase 1